Viewing Study NCT00005810



Ignite Creation Date: 2024-05-05 @ 11:22 AM
Last Modification Date: 2024-10-26 @ 9:05 AM
Study NCT ID: NCT00005810
Status: COMPLETED
Last Update Posted: 2016-07-14
First Post: 2000-06-02

Brief Title: Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
Sponsor: Alliance for Clinical Trials in Oncology
Organization: Alliance for Clinical Trials in Oncology

Study Overview

Official Title: A Phase II Study of Estramustine Docetaxel and Carboplatin With G-CSF Support in Men With Hormone Refractory Prostate Cancer
Status: COMPLETED
Status Verified Date: 2016-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a persons immune system recover from the side effects of chemotherapy

PURPOSE Phase II trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have stage IV prostate cancer that has not responded to hormone therapy
Detailed Description: OBJECTIVES I Determine the response rate objective and PSA response and duration of response to estramustine docetaxel and carboplatin with filgrastim G-CSF support in patients with hormone refractory prostate cancer II Determine the toxicity of this regimen in this patient population

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
CDR0000067811 REGISTRY NCI Physician Data Query httpsreporternihgovquickSearchU10CA031946
U10CA031946 NIH None None